Although specific somatic mutations—such as those in EGFR, KRAS, and EML4-ALK—have been identified, particularly in lung adenocarcinoma, they are absent in the majority of patients with lung cancer (21, 22). This evidence concerns the gene KRAS and lung adenocarcinoma.